Dados B3 › BLAU3 × DASA3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | BLAU3 | DASA3 | year |
|---|---|---|---|
| ROE | 13.3% | -15.6% | 2025 |
| ROIC | 12.2% | 4.2%! | 2025 |
| ROA | 8.4% | -5.0% | 2025 |
| Gross margin | 40.1% | 30.4% | 2025 |
| EBIT margin | 20.8% | 8.1% | 2025 |
| Net margin | 17.4% | -10.2% | 2025 |
| Net debt/EBITDA | -0.04x | 2.45x | 2025 |
| Current ratio | 2.47x | 1.24x | 2025 |
| Revenue growth (1y) | -3.0% | -27.1% | 2025 |
| Revenue growth (5y CAGR) | 7.6% | 9.7% | 2025 |
| Piotroski F-Score | 5/9 | 4/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | BLAU3 | DASA3 | year |
|---|---|---|---|
| P/E | 10.18x | -3.70x | 2025 |
| P/B | 1.32x | 0.62x | 2025 |
| EV/EBITDA | 7.05x | 4.56x | 2025 |
| FCF yield | -4.3% | -7.7% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:48 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it